Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Celgene will pay Prothena $100 million up front as part of a pact to develop antibodies against three neuroscience drug targets: tau, a protein linked to Alzheimer’s disease; TDP-43, a protein implicated in amyotrophic lateral sclerosis; and an undisclosed target. The deal, which also calls for Celgene to take an equity stake in Prothena worth $50 million, comes at a time when Celgene is trying to bolster its neurodegenerative disease pipeline. Celgene can license the U.S. rights to drug candidates after Phase I studies.
This article has been sent to the following recipient: